ImmuneOnco Biopharma is based in Shanghai, China. It has raised $25M in total funding. Backed by Eli Lilly Asia Fund, LYFE Capital, Licheng Assets.
ImmuneOnco Biopharma funding overview
ImmuneOnco Biopharma is based in Shanghai, China. ImmuneOnco Biopharma has raised $25M in total disclosed funding. That places its disclosed total in the $25M–$100M range. The round record for ImmuneOnco Biopharma runs through 2017; nothing later has been disclosed. Investors on record include Eli Lilly Asia Fund, LYFE Capital, Licheng Assets. 3 distinct backers are named across the disclosed rounds.
ImmuneOnco Biopharma at a glance
Total raised
$25M
Latest round date
January 2017
Headquarters
Shanghai, China
Notable investors
Eli Lilly Asia Fund, LYFE Capital, Licheng Assets
Frequently asked about ImmuneOnco Biopharma funding
How much has ImmuneOnco Biopharma raised?
ImmuneOnco Biopharma has raised $25M in total disclosed funding across the rounds on record.
Who has invested in ImmuneOnco Biopharma?
Eli Lilly Asia Fund, LYFE Capital, Licheng Assets are named among the investors backing ImmuneOnco Biopharma.
What was the latest ImmuneOnco Biopharma funding round?
No round stage has been disclosed for ImmuneOnco Biopharma.
Where is ImmuneOnco Biopharma based?
ImmuneOnco Biopharma is based in Shanghai, China.
When did ImmuneOnco Biopharma last raise?
The last disclosed ImmuneOnco Biopharma round closed in January 2017.
ImmuneOnco Biopharma totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shanghai below to benchmark round size and investor mix.
